@FiercePharma: Top-read special report yesterday: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma
@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. Story via MediaPost | Follow @TracyStaton
@EricPFierce: Pacira invests $40M to $50M in a DPx U.K. plant, allowing it to produce an additional $300M in Exparel. Article via FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: So there are no anthropomorphized body parts in this week's FiercePharmaMarketing, but Viagra-flavored ice cream does make an appearance. Edition | Follow @CarlyHFierce
> GlaxoSmithKline ($GSK) says it's investigating bribery allegations in Jordan and Lebanon, following earlier claims of corruption in China, Iraq and Poland. Story
> Boehringer Ingelheim, joining other drugmakers in improving clinical trial transparency, says it will make its data available going back to 1998. Story
> Novartis ($NVS) accidentally sent out a mass email announcing the FDA approval of lung cancer drug Zykadia--a drug the agency has not actually approved yet. News
> The FDA wants drugmakers and others to weigh in on its ideas for its new strategy for health IT products. Blog post
> Teva ($TEVA) has launched a generic of Sunovion's insomnia treatment Lunesta. Report
@FierceMedDev: Report: Cardiac Dimensions raises $20M for heart valve sales in Europe. Story | Follow @FierceMedDev
@VarunSaxena2: FierceBiotech broke story on Novartis stopping RNAi research. I'm interviewing Alnylam on fallout. $ALNY down 20+% since last week. | Follow @VarunSaxena2
@EmilyWFierce: Boston Scientific scores FDA approval for a new crop of implantable cardiac devices. News | Follow @EmilyWFierce
@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article via FierceDrugDelivery | Follow @MichaelGFierce
> St. Jude rides strong ICD sales to a first-quarter bump. More
> Qiagen puts up $10M to boost its diagnostics manufacturing. Piece
Biotech News
@FierceBiotech: Have the biotech bears run out of steam? Item | Follow @FierceBiotech
@JohnCFierce: Column Group nears goal line for $250M biotech venture fund. More | Follow @JohnCFierce
@DamianFierce: TriVascular's IPO prices at $12, below its range, and raises $78 million. Release | Follow @DamianFierce
@EmilyMFierce: ICYMI: Latest issue of FierceBiotech Research features 3-D printing to study cancer and Silly Putty to grow stem cells. More | Follow @EmilyMFierce
> Baxter's latest bleeding drug hits the mark in PhIII. Story
> BioAlliance and Topotarget plan to merge, pooling their cancer pipelines. More
> VCs gamble $96M on rare disease drug, biosimilar play and new drug for AMD. Article
Drug Delivery News
> Study shows nanoparticles can lose their uniform shape, size under lab conditions. More
> Alliqua pulls in $20M to support hydrogel wound care biz. Item
> MIT team delivers three ovarian cancer drugs with one particle. Story
> Magnetic anesthesia: Delivering nerve blocks locally with a targeted approach. Article
> Study: Inhalable encapsulated antibiotic from Aradigm kills 99% of infections. Report
> Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate.' News
Diagnostics News
> Philips touts encouraging results from an early test of its hand-held cardiac blood Dx. More
> UCLA, working with a Chinese partner, will build a high-tech Dx lab in Shanghai. Story
> Qiagen licenses biomarker for rare blood disorders with a molecular Dx in mind. Article
> GE Healthcare's Dineen: A quest for new acquisitions will continue. News
> Sequenom scores a blow against Illumina in prenatal Dx patent fight. More
> An acquisition helps carry ERBA Diagnostics to a (small) 2013 profit. Item
Pharma Marketing News
> Pharma sales force took a hit in North America and Europe in 2013, new report shows. More
> BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency. Story
> How to talk about constipation? Forest's new DTC campaign for Linzess will show you. Article
> Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market. News
> Sanofi beefs up social media channels with Spanish Twitter push. Report
> GlaxoSmithKline bribery probe heats up as Polish prosecutors charge 13 people. Item
And Finally... Sanofi ($SNY) has brought on former WNBA star and coach Nancy Lieberman to help promote its OTC version of allergy med Nasacort, a move it says will help allergy sufferers "put the full 'cort press" on symptoms. Release
Editor's Note: An image in Monday's FiercePharma report should have shown GlaxoSmithKline's headquarters rather than AstraZeneca's to go along with this story. We regret the error and apologize for any confusion.